About the Authors

Frédéric Coutant

Current address: Faculté de médecine Paris Descartes, Paris, France

Affiliation Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France

Raul Yusef Sanchez David

Current address: Unité de Génomique Virale et Vaccination, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France

Affiliation Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France

Tristan Félix

Affiliation Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France

Aude Boulay

Current address: Service d’Epidémiologie, Institut Pasteur de Bangui, BP 923 Bangui, République Centrafricaine

Affiliation Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France

Laxmee Caleechurn

Current address: Laboratoires Clarins S.A., BP147, 95304 Cergy Pontoise Cedex, France

Affiliation Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France

Philippe Souque

Affiliation Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France

Catherine Thouvenot

Affiliation Centre de Production et d’Infection des Anophèles (CEPIA), Department of Parasitology and Mycology, Institut Pasteur, Paris, France

Catherine Bourgouin

Affiliation Centre de Production et d’Infection des Anophèles (CEPIA), Department of Parasitology and Mycology, Institut Pasteur, Paris, France

Anne-Sophie Beignon

Contributed equally to this work with: Anne-Sophie Beignon, Pierre Charneau

asb@pasteur.fr (ASB); pierre.charneau@pasteur.fr (PC)

Affiliation Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France

Pierre Charneau

Contributed equally to this work with: Anne-Sophie Beignon, Pierre Charneau

asb@pasteur.fr (ASB); pierre.charneau@pasteur.fr (PC)

Affiliation Unité Virologie Moléculaire et Vaccinologie, Department of Virology, Institut Pasteur and CNRS URA3015, Institut Pasteur, Paris, France

Competing Interests

We have read the journal’s policy and have the following conflicts. PC is the founder of theravectys, a company whose goal is to develop a therapeutic AIDS vaccine using lentiviral vectors. FC and PC are inventors of a patent titled “Lentiviral vector based immunological compounds against malaria” (international patent application W02011138251 filed on April 24, 2011) and which is owned by the Institut Pasteur. There are no further patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: FC CB ASB PC. Performed the experiments: FC RYSD TF AB LC PS CT ASB. Analyzed the data: FC CB ASB PC. Contributed reagents/materials/analysis tools: CB. Wrote the paper: FC CB ASB PC.